Triad Therapeutics Inc., a homecare infusion therapy and nursing provider in New Jersey serving throughout the states of New Jersey, New York and Connecticut, has become a wholly owned subsidiary of Aperture Health, Inc. Aperture has completed the acquisition of Triad and it will remain as the operating company for the combined business.
Triad provides specialized home healthcare services to patients requiring intravenous therapy including antibiotics, pain management, hydration, immunoglobulins, steroids, total nutritional solutions, and IV catheter insertions and maintenance. The company provides a complete solution to patients including the preparation and delivery of sterile compounded IV medications, supplies and equipment, along with specialized nursing care and teaching of the patient and/or caregivers on the administration of therapies as prescribed by a physician.
Triad is a fully JCAHO accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the states of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad's full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.
All patient clients accepted to Triad's service have been pre-approved for care by the client's health insurance provider. Triad maintains numerous managed care service provider contracts, many of which are part of "closed networks," thus provide strong barriers to entry in the industry.
The business of home infusion therapy is a mature industry with multiple competitors. Triad markets its services to hospital discharge planners, physicians, hospice providers, and veterinarian hospitals. Triad vigorously and successfully competes for client referrals by providing enhanced customer service and reliable cross communication with the patients care givers, nurses, pharmacists and physicians.
James Hennig, RPh, chief executive officer and chairman of the Board of Directors commented, “We are very pleased to become a US publicly listed company which will contribute to our market awareness and provide a platform for the capital necessary for us to implement our growth strategy which includes acquisitions and other joint ventures, as well as, organic growth through new referral sources and product and service enhancements.”
On July 18, 2011, Triad Therapeutics Inc. merged into The company via a reverse merger transaction as consideration for all of the issued and outstanding shares of Triad. The Triad shareholders received a 51 per cent controlling interest in the company. On September 13, 2011, The company executed a 1:500 reverse stock split and issued an additional 21 million shares to Triad Shareholders. Triad is the sole operating entity. Triad was incorporated in Delaware in 2007.